The UK MHRA has become the first regulator in the world to approve for marketing a subcutaneous (SC) version of Roche’s anti-PD-(L)1 cancer immunotherapy, Tecentriq (atezolizumab), which cuts treatment time by up to 75% compared with the intravenous (IV) infusion formulation.
Roche’s Seven-Minute Tecentriq Jab Wins First Ever Regulatory Approval
Tecentriq SC To Be Made Available Under Existing Commercial Deal
The National Health Service in England says it will be the first health system in the world to roll out a subcutaneously administered formulation of Tecentriq, after the UK MHRA became the first drug regulator to approve the product.
